Inozyme Pharma shares are trading higher after the company announced that the FDA granted Fast Track designation to INZ-701 for the treatment of ABCC6 Deficiency.
Portfolio Pulse from Benzinga Newsdesk
Inozyme Pharma shares are trading higher after the company announced that the FDA granted Fast Track designation to INZ-701 for the treatment of ABCC6 Deficiency.
July 02, 2024 | 12:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Inozyme Pharma shares are trading higher following the FDA's Fast Track designation for INZ-701, a treatment for ABCC6 Deficiency. This designation could expedite the drug's development and review process, potentially leading to earlier market entry.
The FDA's Fast Track designation is a significant regulatory milestone that can accelerate the development and review of INZ-701. This increases the likelihood of the drug reaching the market sooner, which is positive news for Inozyme Pharma's stock.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100